Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLiu, Mark C.
dc.contributor.authorChipps, Bradley
dc.contributor.authorMuñoz Gall, Fco. Javier
dc.contributor.authorDevouassoux, Gilles
dc.contributor.authorBergna, Miguel
dc.contributor.authorSmith, Steven G.
dc.date.accessioned2022-01-13T17:33:32Z
dc.date.available2022-01-13T17:33:32Z
dc.date.issued2021-05-10
dc.identifier.citationLiu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, et al. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res. 2021 May 10;22:144.
dc.identifier.issn1465-993X
dc.identifier.urihttp://hdl.handle.net/11351/6793
dc.descriptionAsthma; Asthma treatment; Eosinophils
dc.description.abstractBackground The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficacy outcomes and the relationship between patient baseline characteristics and treatment response. Methods This was a post hoc analysis of OSMO study data (GSK ID:204471; ClinicalTrials.gov No. NCT02654145). Patients with severe eosinophilic asthma uncontrolled by high-dose inhaled corticosteroids, other controller(s) and omalizumab subcutaneously (≥ 4 months) were switched to mepolizumab 100 mg administered subcutaneously. Endpoints included the proportion of responders—i.e. patients achieving a pre-defined clinical improvement in ≥ 1 of the following outcomes: (1) Asthma Control Questionnaire (ACQ)-5 score (≥ 0.5-points), (2) St George’s Respiratory Questionnaire (SGRQ) total score (≥ 4-points), (3) pre-bronchodilator forced expiratory volume in 1s (FEV1; ≥ 100 mL), all at Week 32, and (4) annualised rate of clinically significant exacerbations (≥ 50% reduction). Results Of the 145 patients included, 94%, 83%, 63% and 31% were responders for ≥ 1, ≥ 2, ≥ 3 and 4 outcomes, respectively; 75% and 78% were ACQ-5 and SGRQ score responders, and 50% and 69% were FEV1 and exacerbation responders. Subgroup analyses demonstrated improvements irrespective of baseline blood eosinophil count, prior omalizumab treatment regimen/duration, comorbidities, prior exacerbation history, maintenance oral corticosteroid use, ACQ-5 and SGRQ scores, and body weight/body mass index. Conclusions After switching to mepolizumab, almost all patients with uncontrolled severe eosinophilic asthma on omalizumab achieved a beneficial response in ≥ 1 clinical outcome. Improvements were observed regardless of baseline characteristics.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesRespiratory Research;22
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAsma - Tractament
dc.subjectEosinofília
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshPulmonary Eosinophilia
dc.subject.mesh/drug therapy
dc.subject.meshDrug Substitution
dc.subject.meshTreatment Outcome
dc.titleBenefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12931-021-01733-9
dc.subject.decseosinofilia pulmonar
dc.subject.decs/farmacoterapia
dc.subject.decssustitución de medicamentos
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1186/s12931-021-01733-9
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Liu MC] Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. [Chipps B] Capital Allergy and Respiratory Disease Center, Sacramento, CA, USA. [Munoz X] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciber Enfermedades Respiratorias, Madrid, Spain. [Devouassoux G] Service de Pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, UCB Lyon, Lyon, France. [Bergna M] Respiratory Research, CEMER, Vicente Lopez, Buenos Aires, Argentina. [Smith SG] Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA
dc.identifier.pmid33971856
dc.identifier.wos000656440500002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record